Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple myeloma patient’s life, both before and after treatment with the CAR-T therapy.

Unmet Social Needs Among Cancer Survivors Who Were Concomitant Caregivers: A Cross-Sectional Analysis of the Health Information National Trends Survey To better understand the priorities that guide ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Please provide your email address to receive an email when new articles are posted on . Patient-reported physical function predicts which patients gain greatest survival benefit from daratumumab.

Factors associated with extended hospitals stay following primary THA included non-White race, Medicare/Medicaid status, and various hospital characteristics. Race, insurance status, and hospital ...